Alliances
Hutchison MediPharma has entered into a drug discovery and development agreement with Eli Lilly, Merck KGaA and a beauty care agreement with Procter & Gamble. Those partnerships validate Hutchison MediPharma business model and quality of drug development conducted in China. For China pharmaceutical R&D, Hutchison MediPharma represents a new model of innovative drug discovery & development partnership. This kind of risk/reward and IP sharing model could quickly advance China’s new drug development capability to global level.
In addition, Hutchison MediPharma has formed research and strategic collaborations with the University of California at Los Angeles, Shanghai Institute of Materia Medica, the Genetic and Cell Biology Institute of North-Eastern Normal University, Hong Kong Chinese University, the University of Maryland and Cambridge University. We expect these partnerships to provide Hutchison MediPharma with novel drug targets, assays, compound libraries and clinical expertise to improve the speed and quality of Hutchison MediPharma's research programs. Hutchison MediPharma will continue to investigate and discuss other potential alliances with appropriate organisations.
Hutchison MediPharma is seeking opportunities to collaborate with leading universities, research institutes, and pharmaceutical and biotechnology companies in the following areas:
Strategic Alliances/ Licensing
- Joint drug discovery research
- MOA studies
- Technology platforms
- Natural compound library screening
- Joint clinical development
- In- and out-licensing drug candidates at various stages
Our Current Partners:
Contact Information:
Tel: (86)21 50790088
Fax: (86)21 50793900
Email: BD@hmplglobal.com